Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections

This publication has 10 references indexed in Scilit:

• Invasive Mold Infections After Chimeric Antigen Receptor–Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis
  Clinical Infectious Diseases, 2019
• Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study
  Blood Advances, 2019
• Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy
  Haematologica, 2018
• How to prophylax against invasive fungal infections in adult ALL? An unmet need
  Mycoses, 2018
• Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
  Blood, 2018
• FDA Approval of Tisagenlecleucel
  JAMA, 2017
• Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy study
  Mycoses, 2013
• Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study
  Journal of the Pediatric Infectious Diseases Society, 2012
• A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)
  Journal of Antimicrobial Chemotherapy, 2011
• Faculty Opinions recommendation of Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
  2011